G1 Therapeutics Appoints Mark Avagliano as Chief Business Officer

NEXT STORY
RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA(1) +7.4%, NET INCOME +6.1%
PREV STORY
Axsome Therapeutics To Report Second Quarter 2019 Financial Results On August 8, 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock

NEW YORK, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage ...

author_avatar
NASDAQ Market News

Recro Pharma Announces Successful Top-Line Results from Phase III Safety Study of IV Meloxicam

IV Meloxicam 30mg Continues to Demonstrate Solid Safety and Tolerability Profile Company on Track ...

author_avatar
NASDAQ Market News

Interpace Diagnostics Group Reports Third Quarter 2017 Financial Results, Business Progress and Recent Accomplishments

Q3-2017 Net Revenues of Over $4 Million Growing 27% Over Prior Year Quarter  Represents ...

author_avatar
NASDAQ Market News